China Blood Product Industry Report, 2006-2007 Is Available Now.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c62652) has announced the addition of "China Blood Product Industry Report, 2006-2007" to their offering. Blood product belongs to biological products and is a biological active preparation which collects healthy blood as the raw material and then is made through biological process or separation and purification purification, in religion, the ceremonial removal of what the religion deems unclean. The usual agents of purification are water (as in baptism), bodily alteration (as in circumcision), and fire. technologies. Blood products are irreplaceable in the application of medical emergency and prevention & treatment to some specific diseases. China blood product industry is about to see a fast and steady growth: due to the increasing population, high incidence rate of malignant malignant /ma·lig·nant/ (-nant) 1. tending to become worse and end in death. 2. having the properties of anaplasia, invasiveness, and metastasis; said of tumors. disease and growing national economy, blood product market demands are expected to remain growing at 15% annually; China didn't approve to found new blood product enterprises since 2001, which together with imports limit creates a relatively stable competition environment; after plasma collection stations got restructured, blood product industry chain has become more flexible, which is favor to a long-term Long-term Three or more years. In the context of accounting, more than 1 year. long-term 1. Of or relating to a gain or loss in the value of a security that has been held over a specific length of time. Compare short-term. development; and industrial supervision will be increasingly strict. Since the state started regulating plasma collection stations in 2004, plasma volume collected has been sliding, to 3,000 tons in 2005 and 2006. As plasma collection stations finished the restructuring restructuring - The transformation from one representation form to another at the same relative abstraction level, while preserving the subject system's external behaviour (functionality and semantics). , the plasma volume collected has been gradually increasing but plasma supply still falls short presently. The supply and demand are expected to come to a balance by 2008. When the restructuring is over, plasma volume collected is ready to still play an important role for the blood product enterprises to get developed but more important is the ability to manage plasma source Plasma sources generate plasmas. Excitation of a plasma requires partial ionisation of neutral atoms and/or molecules of a medium. There are several ways to cause ionisation: collisions of energetic particles, strong electric fields acting on bond electrons, or ionising . Plasma source management is mainly focused on plasma source scale management and plasma source quality control. Plasma source quality is measured by collected volume of featured plasma, plasma donors' management and guarantee to plasma security. Plasma price keeps growing steadily even after plasma collection stations are restructured, which is because, on the one hand, plasma supply is gradually coming back but still in short; on the other hand, plasma price is quite transparent and even if the cost is added under the counter, it can be seen on the final price. China still can't meet the demands for plasma during 2006-2008 periods; as a result, human serum albumin serum albumin n. See seralbumin. price will keep high during 2007-2008 periods. Leading enterprises have fostered strong competitive advantages from upstream From the consumer to the provider. See downstream. (networking) upstream - Fewer network hops away from a backbone or hub. For example, a small ISP that connects to the Internet through a larger ISP that has their own connection to the backbone is downstream from the larger -- quantity, quality and management of plasma collection stations to downstream From the provider to the customer. Downloading files and Web pages from the Internet is the downstream side. The upstream is from the customer to the provider (requesting a Web page, sending e-mail, etc.). products' R & D, production and distribution. There will form 2-3 nationwide leader and 5-6 regional leaders in China blood product industry in the future while those small weak enterprises will be phased out. Companies Mentioned: * Hualan Biological Engineering Inc. * Shanghai Shanghai (shăng`hī`, shäng`hī`), city (1994 est. pop. 12,980,000), in, but independent of, Jiangsu prov., E China, on the Huangpu (Whangpoo) River where it flows into the Chang (Yangtze) estuary. RAAS Blood Products Co., Ltd * Rongsheng Pharmaceuticals * Shanghai Institute of Biological Products For more information, visit http://www.researchandmarkets.com/reports/c62652. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion